Download PDF (Inglês)
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Wo 2010/075090 A2
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC. -
Ophthalmic Antihistamines
Ophthalmics for Allergic Conjunctivitis Review 04/12/2011 Copyright © 2004 - 2011 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 10101 Alliance Rd, Ste 201 Cincinnati, Ohio 45242 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, -
Epinastine Hcl Ophthalmic Solution) 0.05% Sterile
NDA 21-565/S-005 Page 2 ELESTAT™ (epinastine HCl ophthalmic solution) 0.05% Sterile DESCRIPTION ELESTAT™ (epinastine HCl ophthalmic solution) 0.05% is a clear, colorless, sterile isotonic solution containing epinastine HCl, an antihistamine and an inhibitor of histamine release from the mast cell for topical administration to the eyes. Epinastine HCl is represented by the following structural formula: C16H15N3 • HCl Mol. Wt. 285.78 Chemical Name: 3-Amino-9, 13b-dihydro-1H-dibenz[c,f]imidazo[1,5-a]azepine hydrochloride Each mL contains: Active: Epinastine HCl 0.05% (0.5 mg/mL) equivalent to epinastine 0.044% (0.44mg/mL); Preservative: Benzalkonium chloride 0.01%; Inactives: Edetate disodium; purified water; sodium chloride; sodium phosphate, monobasic; and sodium hydroxide and/or hydrochloric acid (to adjust the pH). ELESTAT™ has a pH of approximately 7 and an osmolality range of 250 to 310 mOsm/kg. CLINICAL PHARMACOLOGY Epinastine is a topically active, direct H1-receptor antagonist and an inhibitor of the release of histamine from the mast cell. Epinastine is selective for the histamine H1-receptor and has affinity for the histamine H2 receptor. Epinastine also possesses affinity for the α1-, α2-, and 5-HT2 –receptors. Epinastine does not penetrate the blood/brain barrier and, therefore, is not expected to induce side effects of the central nervous system. Fourteen subjects, with allergic conjunctivitis, received one drop of ELESTAT™ in each eye twice daily for seven days. On day seven average maximum epinastine plasma concentrations of 0.04 ± 0.014 ng/ml were reached after about two hours indicating low systemic exposure. -
Allergy Skin Testing: Patient Instructions and Consent Form
ALLERGY SKIN TESTING: PATIENT INSTRUCTIONS AND CONSENT FORM Skin tests are a method of testing for allergic reactions to substances, or allergens, in the environment. A test consists of introducing small amounts of allergens into the skin and noting the development of a positive reaction, which consists of a wheal (swelling) and flare (surrounding area of redness). We employ the prick method, where the skin is pricked with a sharp device that introduces the allergen into the skin. Other allergy testing options include injecting the allergen with needles or going to a lab for blood tests. The entire testing process will take about 30 minutes. We test a variety of important allergens that are found in the Central Florida area including trees, grasses, weeds, molds, dust mites, and animal dander. After administering the allergens, we wait approximately 20 minutes to review the results. A positive reaction occurs when the skin becomes red, raised, and itchy. This skin reaction will gradually dissipate within 30‐60 minutes. Some people will experience local swelling beginning 4‐8 hours after testing. This is not serious and typically no treatment is required. It should disappear in the next few days. Less than 1% of patients may develop a systemic reaction to skin testing, which may consist of any or all of the following symptoms: itchy eyes, nose, or throat, nasal congestion, runny nose, tightness in the throat or chest, wheezing, lightheadedness, nausea or vomiting, hives, or anaphylactic shock. This is very rare, but in the event of such reactions, the staff is fully prepared and emergency equipment is readily available. -
Antihistamines in the Treatment of Chronic Urticaria I Jáuregui,1 M Ferrer,2 J Montoro,3 I Dávila,4 J Bartra,5 a Del Cuvillo,6 J Mullol,7 J Sastre,8 a Valero5
Antihistamines in the treatment of chronic urticaria I Jáuregui,1 M Ferrer,2 J Montoro,3 I Dávila,4 J Bartra,5 A del Cuvillo,6 J Mullol,7 J Sastre,8 A Valero5 1 Service of Allergy, Hospital de Basurto, Bilbao, Spain 2 Department of Allergology, Clínica Universitaria de Navarra, Pamplona, Spain 3 Allergy Unit, Hospital La Plana, Villarreal (Castellón), Spain 4 Service of Immunoallergy, Hospital Clínico, Salamanca, Spain 5 Allergy Unit, Service of Pneumology and Respiratory Allergy, Hospital Clínic (ICT), Barcelona, Spain 6 Clínica Dr. Lobatón, Cádiz, Spain 7 Rhinology Unit, ENT Service (ICEMEQ), Hospital Clínic, Barcelona, Spain 8 Service of Allergy, Fundación Jiménez Díaz, Madrid, Spain ■ Summary Chronic urticaria is highly prevalent in the general population, and while there are multiple treatments for the disorder, the results obtained are not completely satisfactory. The second-generation H1 antihistamines remain the symptomatic treatment option of choice. Depending on the different pharmacokinetics and H1 receptor affi nity of each drug substance, different concentrations in skin can be expected, together with different effi cacy in relation to the histamine-induced wheal inhibition test - though this does not necessarily have repercussions upon clinical response. The antiinfl ammatory properties of the H1 antihistamines could be of relevance in chronic urticaria, though it is not clear to what degree they infl uence the fi nal therapeutic result. Before moving on to another therapeutic level, the advisability of antihistamine dose escalation should be considered, involving increments even above those approved in the Summary of Product Characteristics. Physical urticaria, when manifesting isolatedly, tends to respond well to H1 antihistamines, with the exception of genuine solar urticaria and delayed pressure urticaria. -
Original Article Clinical Efficacy of Levocetirizine Combined with Ebastine in the Treatment of Chronic Urticaria and Their Effect on Serum Cytokines
Int J Clin Exp Med 2019;12(9):11675-11683 www.ijcem.com /ISSN:1940-5901/IJCEM0097567 Original Article Clinical efficacy of levocetirizine combined with ebastine in the treatment of chronic urticaria and their effect on serum cytokines Sheng Wang1, Yang Liu2, Jing Wang3, Jing Zhang1 1Department of Dermatology, Tangshan Gongren Hospital, Tangshan 063000, Hebei Province, China; 2Depart- ment of Anesthesiology, Kailuan General Hospital, Tangshan, Hebei Province, China; 3Department of Dermatology, North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei Province, China Received May 27, 2019; Accepted August 6, 2019; Epub September 15, 2019; Published September 30, 2019 Abstract: Objective: To investigate the clinical efficacy of levocetirizine combined with ebastine in the treatment of chronic urticaria and their effect on serum cytokines. Methods: In total, 234 patients with chronic urticaria were selected as the study subjects and divided into the control group and the experimental group, with 117 patients in each group. The experimental group was treated with levocetirizine combined with ebastine, and the control group was treated with levocetirizine. The clinical efficacy and the incidence of adverse reactions were observed after treatment. The levels of serum tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-10 were detected by enzyme-linked immunosorbent assay (ELISA). Patients were divided into group A (126 patients, cure) and group B (108 patients, markedly effective, effective and ineffective) according to clinical efficacy, and the serum levels of TNF-α, IL-6 and IL-10 were compared between the two groups. The receiver operating characteristic (ROC) curve was used to analyze the value of TNF-α, IL-6 and IL-10 in evaluating the clinical efficacy after treatment for patients with chronic urticaria. -
San Diego ENT
San Diego ENT Allergy Skin Testing Instructions Make sure you review all of your medications with your doctor or the medical assistant when you are scheduled for your allergy test. DON’T’S: • Do note take over-the-counter antihistamines, cold medication, or cough syrup for 10 days prior to the test. This includes Benadryl, Claritin, Zyrtec, Allegra, loratadine, cetirizine, and fexofenadine, Tavist, Dramamine,Atarax, and others. • Do not take prescription antihistamines for 10 days prior to the test including Claritin, Zyrtec, Allegra, loratadine, cetirizine, fexofenadine, and Astelin nasal spray. Also stop antihistamine eye drops 10 days prior to testing. • Do not take beta blockers 5 days prior to testing. These include labetalol, metoprolol, carvedilol, and their brand name equivalents. • Do not take anti-acid medication for 48 hours prior to testing including Zantac, Pepcid, and Tagamet. You may continue to take proton pump inhibitors such as Prilosec, Nexium, Prevacid, Protonix, and Aciphex. • Do not take any sleeping medications for 48 hours prior to testing including Tylenol PM and Excedrin PM. DO’S: • Wear something comfortable that will allow access to your back or both upper arms on the day of testing. • You may continue to use nasal steroid sprays such as Flonase, Nasonex, Nasacort, and Rhinocort. Do not use Astelin. • Review the list of medications that need to be avoided below. Antihistamines to stop 10 days prior to testing: Generic Brand Name Acrivastine Semprex Azatadine Optimine, Trinalin Bropheniramine AccuHist, Bromfed, -
Pharmaceuticals As Environmental Contaminants
PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational -
Skin Lesions in Patients Treated with Imatinib Mesylate: a 5-Year Prospective Study
Skin Lesions in Patients Treated With Imatinib Mesylate: A 5-Year Prospective Study Giovanni Paolino, MD; Dario Didona, MD; Rita Clerico, MD; Paola Corsetti, MD; Marina Ambrifi, MD; Ugo Bottoni, PhD; Stefano Calvieri, PhD PRACTICE POINTS • The most common cutaneous adverse reactions from imatinib mesylate (IM) are swelling and edema. • Maculopapular rash with pruritus is one of the most common side effects from IM and can be effectively treated with oral or systemic antihistamines. • The onset of periorbital edema requires a complete evaluation of renalcopy function. not Imatinib mesylate (IM) represents the first-line matinib mesylate (IM) represents the first-line treatment of patients with chronic myeloid leu- treatment of chronic myeloid leukemia (CML) kemia (CLM) or gastrointestinal stromal tumorDo I and gastrointestinal stromal tumors (GISTs). (GIST). It presents several side effects. However, Its pharmacological activity is related to a spe- less than 10% are nonhematologic including cific action on several tyrosine kinases in different nausea, vomiting, diarrhea, muscle cramps, and tumors, including Bcr-Abl in CML, c-Kit (CD117) cutaneous reactions. The aim of our study was in GIST, and platelet-derived growth factor receptor to identify data regarding IM cutaneous adverse in dermatofibrosarcoma protuberans.1,2 effects (AEs) to improve the clinical diagnosis and Imatinib mesylate has been shown to improve management of the more frequent side effects. progression-free survival and overall survival2; how- Skin examination shouldCUTIS be done before and ever, it also has several side effects. Among the during IM treatment so that AEs can be diagnosed adverse effects (AEs), less than 10% are nonhema- and treated early with less impact on chemo- tologic, such as nausea, vomiting, diarrhea, muscle therapy treatments and on the quality of life of cramps, and cutaneous reactions.3,4 the patient. -
National PBM Drug Monograph Epinastine (Elestat™) May 2004 VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel
National PBM Drug Monograph Epinastine (Elestat™) May 2004 VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel EXECUTIVE SUMMARY • Antihistamine ophthalmic drops provide quick relief from allergic conjunctivitis (AC) symptoms such as itching and redness, without the potential adverse effects associated with systemic absorption. • Epinastine is the fourth ophthalmic antihistamines/mast cell stabilizer approved for the itching associated with AC. Other ophthalmic preparations for allergic conjunctivitis include antihistamines, mast cell stabilizers, nonsteroidal anti-inflammatory agents (NSAIDs), corticosteroids, decongestants, and decongestant/antihistamines. • An ideal agent would offer improved efficacy and safety, reduce polypharmacy as a combination product or through replacing oral agents, and provide evidence for chronic AC prevention. INTRODUCTION1 The purposes of this monograph are to (1) evaluate the available evidence of safety, tolerability, efficacy, cost, and other pharmaceutical issues that would be relevant to evaluating epinastine ophthalmic solution for possible addition to the VA National Formulary (VANF); (2) define its role in therapy; and (3) identify parameters for its rational use in the VA. PHARMACOLOGY/PHARMACOKINETICS1, 2 Antihistamines are receptor antagonists used to avoid the inflammatory effects of histamine. Taken orally, these agents have been shown to be effective for treating allergic symptoms such as pruritis (itching). Epinastine in particular has been found to have a rapid onset of action.3 Topical antihistamine eye drops provide relief from ocular symptoms without systemic absorption or related adverse events, allowing for the combination of oral and topical agents when indicated. Ophthalmic antihistamine/mast cell stabilizers such as epinastine combine H1-receptor actions to block ocular itching and redness with H2-receptor affinity. -
Customs Tariff - Schedule
CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels. -
(12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.